Teva Pharmaceutical (TEVA) — This pharmaceutical company known for its biogenerics and active pharmaceutical ingredients (APIs) has been in a bull market since 1999.
Its powerful advance makes it an institutional favorite, so whenever it falls to its 50-day moving average, buyers seem to rush into the stock.
On Feb. 12, I said, “The recent pullback to the 50-day moving average resulted in the normal buying, but shoved it from a small flag that tells us that the advance will more than likely continue with a target in the mid-$60s or higher.”
Last week’s breakaway gap on huge volume suggests that TEVA could just be starting another major move higher.
But the recent run-up also adds to the risk of buying at the current level. New investors may want to buy a half position now and add to it on a pullback to $60.
S&P rates TEVA a “five-star strong buy” with a price objective of $70.
Related Articles:
- Spring Cleaning: 6 Stocks to Sell
- Ride the Greenback With This Dollar ETF
- Long Shot Bet in PALM Could Pay Out Big
The Options Trader’s Guide to Technical Analysis
In his latest report, learn how John Lansing leverages the power of technical analysis to identify the short window when a trade is set to go straight up or down. Get your FREE copy here!
